- Home
- GNLX vs ASRT Comparison
GNLX vs ASRT Comparison
Compare GNLX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNLX | ASRT |
|---|---|---|
| Founded | 2001 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.4M | 75.1M |
| IPO Year | 2023 | 1997 |
Fundamental Metrics
Financial Performance| Metric | GNLX | ASRT |
|---|---|---|
| Price | $4.54 | $9.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $19.75 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 104.6K | 53.3K |
| Earning Date | 11-05-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $1.99 | $7.71 |
| 52 Week High | $8.54 | $15.15 |
Technical Indicators
Market Signals| Indicator | GNLX | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 89.36 |
| Support Level | $4.21 | $8.61 |
| Resistance Level | $4.46 | $10.42 |
| Average True Range (ATR) | 0.24 | 0.27 |
| MACD | 0.08 | 0.99 |
| Stochastic Oscillator | 88.52 | 89.19 |
Price Performance
Historical ComparisonAbout GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.